{"id":15391,"date":"2022-02-09T00:00:00","date_gmt":"2022-02-09T00:00:00","guid":{"rendered":"https:\/\/cms.alj3.clients.lemonhq.io\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/"},"modified":"2026-05-12T13:28:20","modified_gmt":"2026-05-12T13:28:20","slug":"healthcare-for-the-many-not-only-the-few-7","status":"publish","type":"perspectives","link":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/","title":{"rendered":"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k"},"content":{"rendered":"<h4>A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine.<\/h4>\n<p>In June 2021, <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a> and <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a>, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully approved by all relevant authorities &#8211; to a potential 1.5 billion people across the Middle East, Africa and Turkey.<\/p>\n<p>The two oncology programs, aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor and sugemalimab, an anti-PD-L1 antibody, have shown promising Phase 3 data for the treatment of patients with advanced non-small cell lung cancer (NSCLC).\u00a0 \u00a0These therapies have the potential to offer treatment at a fraction of the cost of existing approaches.<\/p>\n<p>This collaboration will see Abdul Latif Jameel Health commercialize the drugs to selected markets throughout the Middle East region, as well as in Turkey and all of Africa, providing access to affordable, safe, effective treatment for thousands of lung cancer patients.<\/p>\n<p>We spoke to <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a>, Chief Executive Officer, EQRx, and <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a>, CEO, Abdul Latif Jameel Health, about the partnership and what it could mean for cancer patients in the target markets.<\/p>\n<h2>Melanie, can you tell us about your mission at EQRx?<\/h2>\n<div id=\"attachment_95745\" style=\"width: 231px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95745\" class=\"size-medium wp-image-95745\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/><p id=\"caption-attachment-95745\" class=\"wp-caption-text\">Melanie Nallicheri,<br \/>CEO, EQRx<\/p><\/div>\n<p><strong>MN: <\/strong>Our mission is to improve health for all through great innovative, affordable medicines:<\/p>\n<ul>\n<li>so that people around the world can access these medicines for chronic or life-threatening diseases or conditions without any barriers;<\/li>\n<li>so prescribers around the world can offer them to their patients without unnecessary administrative challenges; and,<\/li>\n<li>so payers and health systems around the world can make these medicines available to patients in a financially sustainable way.<\/li>\n<\/ul>\n<p>What we are basically saying is, we want to make innovative, life-enhancing medicines available and accessible to patients all over the world.<\/p>\n<h2>Why are the issues of accessibility and affordability such big problems in the pharmaceutical industry?<\/h2>\n<p><strong>MN: <\/strong>Our understanding of medicine, biology and data science has developed enormously in recent years. \u00a0Things we can do today would have been seen as science fiction a decade or two ago. \u00a0What usually happens\u00a0 as technology moves forward, costs \u2013 or at least consumer prices \u2013 come down. \u00a0But in healthcare, costs have actually gone up. \u00a0This means our understanding and our capabilities have increased, but the accessibility and affordability of these new solutions has decreased. \u00a0We could see this was wrong, and we saw an opportunity to do things differently by building a successful business at scale to change this dynamic.<\/p>\n<div id=\"attachment_95752\" style=\"width: 283px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95752\" class=\"size-medium wp-image-95752\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/><p id=\"caption-attachment-95752\" class=\"wp-caption-text\">Dr. Akram Bouchenaki,<br \/>CEO, Abdul Latif Jameel Health<\/p><\/div>\n<p><strong>AB: <\/strong>To add to Melanie\u2019s point, there is an incredible unmet medical need for these drugs.\u00a0 If you look at the Gulf region, which generally has a good level of healthcare, lung cancer is the second most common cancer in men, and it is the leading cause of death by cancer in men.\u00a0 Up to 80 percent of cases are diagnosed at advanced stages, and the five-year survival is as low as 10 to 20 percent.<\/p>\n<p>This is why it is absolutely critical to massively expand access to these therapies.\u00a0 That\u2019s the vision that we\u2019re trying to implement.<\/p>\n<h2>This isn\u2019t a new problem, so what is different about EQRx\u2019s approach to addressing it?<\/h2>\n<p><strong>MN: <\/strong>We recognized that to make a real difference, you need a significant portfolio, or catalog, of medicines. \u00a0This allows you to offer many choices for treating chronic or life-threatening diseases and enables you to make the greatest impact. \u00a0Instead of starting with one or two drugs, we wanted to start with 10, 20, 30, focusing on critical areas like oncology and immune-inflammatory diseases.<\/p>\n<p>We are also coming at the problem from a different perspective, from the basis of a shared objective with prescribers and payers. \u00a0Normally a manufacturer will launch a great new drug, but they keep the price high to maximize their profits and keep their shareholders happy. \u00a0Prescribers want to offer this drug to their patients, while payers \u2013 like health insurers or national health schemes \u2013 want to make it available to their members and communities. \u00a0The problem is, the cost is so high they can only afford to prescribe to a certain number of people, otherwise it would blow their budget. \u00a0This means they have to restrict who can benefit from these drugs.\u00a0 In effect, the objectives of the manufacturers, the prescribers\/payers and the patients are at odds with each other.<\/p>\n<p>Our approach is to work towards a <em>shared objective<\/em> of making these medicines as widely available as possible. \u00a0To do this, we intend to make our pricing\u00a0 transparent, simple and radically lower. \u00a0We will benefit from selling more of our medicines, prescribers and payers benefit from offering these treatments to more people without breaking their budgets, and patients benefit from having access to life-enhancing healthcare.<\/p>\n<h2>How big a difference could this make for health systems as well as for patients?<\/h2>\n<p><strong>MN: <\/strong>The potential benefits are enormous.\u00a0 Our mission is to offer life-changing medicines at radically lower prices.\u00a0 By radically lower, we\u2019re talking a quarter, a third, a half lower.\u00a0 That makes a significant difference.\u00a0 For example, say there is a total global spend for a specific drug of US$ 10 billion, which isn\u2019t inconceivable for many immune-inflammatory diseases.\u00a0 Our drug might be priced at a third of the price of the current drug, so in a market of US$ 10 billion, there is immediately a potential saving of over US$ 6.6 billion.\u00a0 Of course, we\u2019re never going to own 100% of a market, but even if we only had 15% of the market \u2013 US$ 1.5 billion \u2013 by offering our drug at one-third of the price, that\u2019s still US$500 million in revenue for us and a saving of US$ 1 billion for the health system.\u00a0 So you can see how we can potentially build a great business yet also generate significant value for all of the other stakeholders in our ecosystem, not least the patients, who will have access to treatments that may have been previously unavailable to them.<\/p>\n<div id=\"attachment_95724\" style=\"width: 2277px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95724\" class=\"size-full wp-image-95724\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/><p id=\"caption-attachment-95724\" class=\"wp-caption-text\">Pictured (L-R) Alexis Borisy, Executive Chairman, Board of Directors &amp; Melanie Nallicheri, Chief Executive Officer EQRx<br \/>Photo credit \u00a9 Fierce Biotech.<\/p><\/div>\n<h2>How has EQRx been able to overcome the barriers that have stopped someone doing this before?<\/h2>\n<p><strong>MN: <\/strong>There are three core pillars in our business model that we believe will enable us to do this. \u00a0The first is that, right from day one, we have had a laser-sharp focus on creating a completely different cost structure.\u00a0 We are a new business, so we\u2019ve been able to create that structure from the ground up right across the organization.\u00a0 Second, we are creating operational processes that leverage everything we have at our disposal as an industry to lower the cost of developing the medicine. \u00a0For instance, you can use remote approaches to monitor patients during a clinical trial, which means you can conduct trials much faster and more efficiently, which reduces costs.\u00a0 Lastly, because of this unique business model, we don\u2019t need the typical salesforce-driven, high-promotion approach to selling drugs.\u00a0 Our partners should be creating the pull-through and the access to our medicines, as opposed to us sending hundreds of salespeople to persuade people to buy them.\u00a0 This kind of market-driven model has not existed before in the global healthcare sector.<\/p>\n<h2>Akram, what was it about EQRx that convinced you they would be good partners for Abdul Latif Jameel Health?<\/h2>\n<p><strong>AB<\/strong>: As we were looking to become an investor in EQRx, we found a great alignment with the vision, the values and the overall purpose of EQRx. \u00a0Abdul Latif Jameel Health aims to be a bridge to accelerate access to innovative therapies in the global south. \u00a0\u00a0The two key words there are \u2018accelerate&#8217; and \u2018access\u2019.\u00a0 We want to get vital medicines \u00a0to people faster and make them accessible to more people.\u00a0 Affordability is a key part of that, but price is not the only factor preventing medicines reaching those who need them.\u00a0 I\u2019ve been in situations in my career where we have donated tons of drugs to treat infectious disease to countries where prevalence rates were very high, but unfortunately the drugs never made it to the patients who needed them. \u00a0So, there is more than just an affordability issue to address.<\/p>\n<p>The other thing we really liked with the EQRx approach is that we saw a great alignment with the innovative business model they are building, the way they\u2019re focusing on the right stakeholders for the future. \u00a0It is a vision and a strategy that we very much support and look forward to implementing in our part of the world.<\/p>\n<h2>Melanie, your first two products are both cancer drugs &#8211; aumolertinib and sugemalimab. Why did you choose to start with these two?<\/h2>\n<p><strong>MN: <\/strong>When we first started, we said we wanted to have our first drug available to patients within five years.\u00a0 That was part of our thinking when we were scanning the market for medicines to bring into our portfolio.\u00a0 Both aumolertinib and sugemalimab are for non-small-cell lung cancer, as well as other cancers.\u00a0 Aumolertinib is a targeted therapy in oncology for patients with EFGR-driven mutations.\u00a0 Sugemalimab is an immunotherapy. \u00a0In cancer, it\u2019s the largest drug class that we know today.<\/p>\n<p>We were very excited about these drugs, both of which have been shown to have excellent efficacy and a strong tolerability profile.<\/p>\n<p>Not only that, these two medicines could be available as early as 2023, which is much sooner than our original five-year target.\u00a0 This means we can start having conversations with regulatory agencies around the world, and with our partners around the world, to start the process of getting these drugs to the people that need them.\u00a0 It\u2019s the ideal scenario: a great medicine with a great tolerability profile, much sooner than we had originally anticipated. \u00a0That\u2019s why we were so excited about these two therapeutics.<\/p>\n<h2>Akram, how do you plan to leverage Abul Latif Jameel\u2019s global footprint to get these drugs to those who need them?<\/h2>\n<p><strong>AB:<\/strong> \u00a0This is the kind of challenge for which Abdul Latif Jameel Health was designed.\u00a0 It was the vision of <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> that we become a critical part of the innovation chain, because innovation is not just what happens in the lab.\u00a0 That\u2019s the starting point, of course, but innovation is also about finding new ways, faster and more effective ways, to deliver those therapies to patients.\u00a0 We see ourselves as the deliverers of that promise of innovation.\u00a0 These drugs are going to be absolutely central in transforming patient care, in prolonging life, in making cancer treatment better tolerated.\u00a0 The promise is there, and we see delivery as an integral part of that innovation journey.<\/p>\n<h2>What do you see as the biggest challenges for EQRx in achieving your ambitions?<\/h2>\n<p><strong>MN<\/strong>: \u00a0Our first challenge is to develop our catalogue of medicines and build up our organization at scale.\u00a0 To do that you need to be able to do two things. \u00a0One, you need to attract some of the best talent in the entire industry. \u00a0Two, you need to be able to mobilize significant capital to build an enterprise rapidly at scale. \u00a0We\u2019ve been working really diligently from the get-go on both. \u00a0On the people front, we have established a talent brand that\u2019s really unique, both because of our social mission, which is really exciting to people, and also because of the culture at EQRx that rewards enterprise and innovation. \u00a0People are encouraged and empowered to try to do things differently, even if we know that some of the ideas might not work.<\/p>\n<p><strong>AB: \u00a0<\/strong>For us, the challenge is to implement this uniquely innovative and disruptive model.\u00a0 We need to go out and change people\u2019s perceptions about how the drug market works.\u00a0 We don\u2019t want to have armies of sales reps hovering around corridors in hospitals, which is a huge waste of productive time, but rather focus on service, education, distribution.\u00a0 Partnering with healthcare authorities, regulators, and healthcare providers in general is going to be a key success factor for us as we build a new model of medicine where patients are actors in their own health.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-95731 aligncenter\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\n<h2>Finally, what\u2019s next for you both?<\/h2>\n<p><strong>MN:<\/strong> \u00a0We\u2019ll be focusing on building our catalogue and our organization.\u00a0 We have over 10 programs in our portfolio right now. \u00a0Of these, five are clinical-stage programs, including aumolertinib and sugemalimab.\u00a0 We also have another immunotherapy option in our portfolio. \u00a0We have a breast cancer drug, and we have a drug for major immuno-inflammatory diseases, like rheumatoid arthritis and atopic dermatitis. \u00a0After those, we have several earlier-stage programs that we\u2019re developing. \u00a0These include both oncology and immuno-inflammatory diseases, and then most recently, we\u2019ve announced several drug engineering collaborations with companies.\u00a0 By 2025 or 2026, we expect to be addressing more than 20% of the spend of a trillion-dollar global branded drug market. \u00a0And that\u2019s a hugely exciting prospect.<\/p>\n<p><strong>AB<\/strong>: \u00a0We can\u2019t wait to be part of that journey.\u00a0 We\u2019re looking forward to working with Melanie and the team at EQRx and really starting to put our strategy into practice.\u00a0 That\u2019s when the work really starts.\u00a0 We\u2019re super-excited. \u00a0We would love to see patients get access to these exciting new drugs as soon as we possibly can, and we\u2019ll do all we can to achieve that over the next few years, and hopefully beyond.<\/p>\n","protected":false},"featured_media":15377,"menu_order":0,"template":"","class_list":["post-15391","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel\" \/>\n<meta property=\"og:description\" content=\"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Abdul Latif Jameel\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T13:28:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1511\" \/>\n\t<meta property=\"og:image:height\" content=\"868\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/\",\"url\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/\",\"name\":\"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel\",\"isPartOf\":{\"@id\":\"https:\/\/10.0.2.222\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"datePublished\":\"2022-02-09T00:00:00+00:00\",\"dateModified\":\"2026-05-12T13:28:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage\",\"url\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"contentUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"width\":1511,\"height\":868},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/10.0.2.222\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/10.0.2.222\/en\/#website\",\"url\":\"https:\/\/10.0.2.222\/en\/\",\"name\":\"Abdul Latif Jameel\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/10.0.2.222\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"tr_TR","og_type":"article","og_title":"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel","og_description":"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]","og_url":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/","og_site_name":"Abdul Latif Jameel","article_modified_time":"2026-05-12T13:28:20+00:00","og_image":[{"width":1511,"height":868,"url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tahmini okuma s\u00fcresi":"11 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/","url":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/","name":"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k - Abdul Latif Jameel","isPartOf":{"@id":"https:\/\/10.0.2.222\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage"},"image":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage"},"thumbnailUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","datePublished":"2022-02-09T00:00:00+00:00","dateModified":"2026-05-12T13:28:20+00:00","breadcrumb":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#primaryimage","url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","contentUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","width":1511,"height":868},{"@type":"BreadcrumbList","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/perspectives\/healthcare-for-the-many-not-only-the-few-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/10.0.2.222\/en\/"},{"@type":"ListItem","position":2,"name":"K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k"}]},{"@type":"WebSite","@id":"https:\/\/10.0.2.222\/en\/#website","url":"https:\/\/10.0.2.222\/en\/","name":"Abdul Latif Jameel","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/10.0.2.222\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"}]}},"post-meta-fields":{"_wp_page_template":["default"],"_published_date":["field_6057129b493f5"],"published_date":["20220209"],"_location":["field_601267396ce72"],"location":["Dubai, BAE"],"_featured":["field_601a3b473c5c5"],"featured":["0"],"_footnotes":["field_66fd39afb9383"],"footnotes":[""],"_business_sector":["field_66f6b5bcac8cb"],"business_sector":["Sa\u011fl\u0131k"],"_content_series":["field_66fe3c439f8f6"],"content_series":[""],"_old_post_id":["field_66fe3fd59f8f7"],"old_post_id":["95767"],"_short_title":["field_60925d67125ef"],"short_title":["K\u00fc\u00e7\u00fck bir az\u0131nl\u0131k i\u00e7in de\u011fil, herkes i\u00e7in sa\u011fl\u0131k"],"_summary":["field_6019304103a20"],"summary":["<p>EQRx CEO\u2019su Melanie Nallicheri ile ila\u00e7 sekt\u00f6r\u00fcn\u00fc ba\u015ftan yaratacak \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda Soru-Cevap oturumu.<\/p>"],"_mobile_featured_image":["field_66f6b4bee65f3"],"mobile_featured_image":["https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg"],"_push_notification":["field_66f6b47de65f1"],"push_notification":[""],"_publish_mobile":["field_66f6b491e65f2"],"publish_mobile":["0"],"_status":["field_652694983fe12"],"status":["publish"],"_thumbnail_id":["15377"],"_wpml_word_count":["{\"total\":1967,\"to_translate\":{\"ar\":1967,\"zh-hans\":1967,\"fr\":1967,\"ja\":1967,\"es\":1967,\"tr\":1967}}"],"_last_translation_edit_mode":["native-editor"],"amazonS3_cache":["a:12:{s:88:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:96:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:98:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:119:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:113:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:121:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:160:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:162:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:73:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}s:75:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}}"],"_edit_lock":["1778592424:22"],"content":["<h4>EQRx CEO\u2019su Melanie Nallicheri ile ila\u00e7 sekt\u00f6r\u00fcn\u00fc ba\u015ftan yaratacak \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda Soru-Cevap oturumu.<\/h4>\r\n<p>2021\u2019in Haziran ay\u0131nda <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a>, daha d\u00fc\u015f\u00fck fiyatlarla \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lar geli\u015ftirmeyi ve sunmay\u0131 taahh\u00fct eden biyoteknoloji \u015firketi <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a> ile uygun fiyatl\u0131 iki yeni akci\u011fer kanseri ilac\u0131n\u0131n da\u011f\u0131t\u0131m\u0131 i\u00e7in stratejik i\u015f birli\u011fi anla\u015fmas\u0131 imzalad\u0131. Bu ila\u00e7lar\u0131n, t\u00fcm yetkili kurumlardan gerekli t\u00fcm onaylar\u0131 ald\u0131ktan sonra Orta Do\u011fu, Afrika ve T\u00fcrkiye\u2019de potansiyel olarak 1,5 milyar ki\u015fiye ula\u015fmas\u0131 bekleniyor.<\/p>\r\n<p>Epidermal b\u00fcy\u00fcme fakt\u00f6r\u00fc resept\u00f6r\u00fc (Epidermal Growth Factor Receptor, EGFR) inhibit\u00f6r\u00fc olan \u201caumolertinib\u201d ve anti-PD-L1 antikoru olan \u201csugemalimab\u201d adl\u0131 iki onkoloji program\u0131, ilerlemi\u015f k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri (Non-Small Cell Lung Cancer, NSCLC) hastalar\u0131n\u0131n tedavisi i\u00e7in umut verici Faz 3 verileri ortaya koydu. Bu tedaviler, mevcut yakla\u015f\u0131mlar\u0131n \u00e7ok alt\u0131nda maliyetlerle tedavi imkan\u0131 sunma potansiyeline sahip.<\/p>\r\n<p>Bu i\u015f birli\u011fi ile Abdul Latif Jameel Health, bu ila\u00e7lar\u0131 Orta Do\u011fu b\u00f6lgesi, T\u00fcrkiye ve t\u00fcm Afrika genelindeki se\u00e7ili pazarlarda piyasaya s\u00fcrecek ve akci\u011fer kanseriyle m\u00fccadele eden binlerce ki\u015fi i\u00e7in uygun fiyatl\u0131, g\u00fcvenli ve etkili tedavilere eri\u015fim imkan\u0131 sa\u011flayacak.<\/p>\r\n<p>EQRx \u0130cra Kurulu Ba\u015fkan\u0131 <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a> ve Abdul Latif Jameel Health \u0130cra Kurulu Ba\u015fkan\u0131 <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a> ile ortakl\u0131k hakk\u0131nda konu\u015ftuk ve bu ortakl\u0131\u011f\u0131n hedef pazarlardaki kanser hastalar\u0131 i\u00e7in ne anlama gelebilece\u011fi konusunda bilgi edindik.<\/p>\r\n<h2>Sn. Nallicheri, EQRx olarak misyonunuzdan biraz bahseder misiniz?<\/h2>\r\n\r\n[caption id=\"attachment_95751\" align=\"alignright\" width=\"221\"]<img class=\"size-medium wp-image-95751\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/> Melanie Nallicheri<br \/>\r\nEQRx \u0130cra Kurulu Ba\u015fkan\u0131[\/caption]\r\n\r\n<p><strong>MN: <\/strong>Misyonumuz, yenilik\u00e7i ve uygun fiyatl\u0131 muhte\u015fem ila\u00e7larla herkese daha sa\u011fl\u0131kl\u0131 bir hayat sunmak. B\u00f6ylece:<\/p>\r\n<ul>\r\n\t<li>D\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki insanlar\u0131n kronik veya hayat\u0131 tehdit eden hastal\u0131klara ya da rahats\u0131zl\u0131klara kar\u015f\u0131 gerekli ila\u00e7lara herhangi bir engel olmadan eri\u015febilmesini,<\/li>\r\n\t<li>D\u00fcnyan\u0131n her neresinde olursa olsun, re\u00e7ete yazan t\u00fcm sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131n\u0131n gereksiz idari zorluklar olmadan hastalar\u0131na bu ila\u00e7lar\u0131 sunabilmesini ve<\/li>\r\n\t<li>T\u00fcm d\u00fcnyadaki sigorta \u015firketlerinin ve sa\u011fl\u0131k sistemlerinin bu ila\u00e7lar\u0131 hastalara finansal olarak s\u00fcrd\u00fcr\u00fclebilir bir \u015fekilde sunabilmesini sa\u011flamay\u0131 hedefliyoruz.<\/li>\r\n<\/ul>\r\n<p>K\u0131sacas\u0131; yenilik\u00e7i ve ya\u015fam standartlar\u0131n\u0131 geli\u015ftiren ila\u00e7lar\u0131, d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki hastalar\u0131n kullan\u0131m\u0131na sunmak ve eri\u015filebilir k\u0131lmak istiyoruz.<\/p>\r\n<h2>\u0130la\u00e7 end\u00fcstrisinde eri\u015filebilirlik ve uygun fiyat neden bu kadar b\u00fcy\u00fck bir sorun te\u015fkil ediyor?<\/h2>\r\n<p><strong>MN: <\/strong>T\u0131p, biyoloji ve veri bilimi alanlar\u0131nda son y\u0131llarda \u00e7ok b\u00fcy\u00fck geli\u015fmeler kaydettik. Bug\u00fcn yapabildi\u011fimiz \u015feyler, bundan 10-20 y\u0131l \u00f6nce ancak bilim kurgu filmlerinde g\u00f6r\u00fclebilecek \u015feylerdi. Normalde, teknoloji geli\u015ftik\u00e7e genellikle maliyetlerin ya da en az\u0131ndan t\u00fcketici fiyatlar\u0131n\u0131n d\u00fc\u015ft\u00fc\u011f\u00fc g\u00f6zlemlenir. Ancak sa\u011fl\u0131k hizmetlerinde aksi \u015fekilde maliyetler artt\u0131. Bu da \u015funa i\u015faret ediyor: Bilimsel bilgi ve becerilerimiz artarken yeni t\u0131bbi \u00e7\u00f6z\u00fcmlerin eri\u015filebilirli\u011fi ve maddi olarak ula\u015f\u0131labilirli\u011fi azald\u0131. Bunun yanl\u0131\u015f bir durum oldu\u011funu g\u00f6rebiliyorduk, bu sayede bu dinami\u011fi de\u011fi\u015ftirmek i\u00e7in b\u00fcy\u00fck \u00f6l\u00e7ekli ve ba\u015far\u0131l\u0131 bir i\u015fletme olu\u015fturarak i\u015fleri farkl\u0131 \u015fekilde yapma f\u0131rsat\u0131 g\u00f6rd\u00fck.<\/p>\r\n<p><strong>AB: <\/strong>Melanie\u2019nin s\u00f6ylediklerine ek olarak bu ila\u00e7lara y\u00f6nelik inan\u0131lmaz seviyede bir ihtiya\u00e7 oldu\u011funu belirtmek isterim. Bu kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyac\u0131 \u015fu \u015fekilde \u00f6rnekleyebilirim: Sa\u011fl\u0131k hizmetleri konusunda genel olarak iyi bir d\u00fczeyde olan K\u00f6rfez Arap \u00dclkeleri \u0130\u015fbirli\u011fi Konseyi b\u00f6lgesine bakt\u0131\u011f\u0131m\u0131zda, akci\u011fer kanserinin erkeklerde en yayg\u0131n ikinci kanser t\u00fcr\u00fc oldu\u011funu ve erkeklerde \u00f6l\u00fcmle sonu\u00e7lanan kanser t\u00fcrlerinde birinci s\u0131rada oldu\u011funu g\u00f6r\u00fcyoruz. Vakalar\u0131n y\u00fczde 80\u2019ine yak\u0131n\u0131 ileri evrelerde te\u015fhis ediliyor ve be\u015f y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131 %10-20 gibi d\u00fc\u015f\u00fck seviyelerde.<\/p>\r\n<p>Bu nedenle bu tedavilere eri\u015fimi \u00e7ok b\u00fcy\u00fck \u00e7apta art\u0131rmak kesinlikle kritik \u00f6nem ta\u015f\u0131yor. Uygulamaya \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z vizyon bu.<\/p>\r\n<h2>Bu yeni bir sorun de\u011fil. Peki EQRx\u2019in bu sorunu ele alma yakla\u015f\u0131m\u0131ndaki fark ne?<\/h2>\r\n<p><strong>MN: <\/strong>Ger\u00e7ek bir fark yaratmak i\u00e7in \u00f6nemli bir ila\u00e7 portf\u00f6y\u00fcne veya katalo\u011funa ihtiya\u00e7 oldu\u011funu fark ettik. B\u00f6ylece, kronik veya ya\u015fam\u0131 tehdit eden hastal\u0131klar\u0131 tedavi etmek i\u00e7in bir\u00e7ok se\u00e7enek sunabilecek ve m\u00fcmk\u00fcn olan en b\u00fcy\u00fck etkiyi yaratma imkan\u0131na sahip olabilecektik. Bunu g\u00f6z \u00f6n\u00fcnde bulundurarak, bir veya iki ila\u00e7la ba\u015flamak yerine 10, 20, 30 ila\u00e7 ile ba\u015flamak istedik ve onkoloji ve imm\u00fcn-enflamatuvar hastal\u0131klar gibi kritik alanlara odakland\u0131k.<\/p>\r\n<p>Ayn\u0131 zamanda bu soruna, re\u00e7ete yazan sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 ve sigorta \u015firketleri ile ortak bir hedef temelinde farkl\u0131 bir perspe<\/p>\r\n\r\n[caption id=\"attachment_95758\" align=\"alignright\" width=\"273\"]<img class=\"size-medium wp-image-95758\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/> Dr. Akram Bouchenaki<br \/>\r\nAbdul Latif Jameel Health CEO\u2019su[\/caption]\r\n\r\n<p>ktiften de yakla\u015f\u0131yoruz. Normalde bir \u00fcretici, yeni bir ila\u00e7 piyasaya s\u00fcrece\u011fi zaman k\u00e2r\u0131n\u0131 en \u00fcst d\u00fczeye \u00e7\u0131karmak ve hissedarlar\u0131n\u0131 mutlu etmek i\u00e7in fiyat\u0131 y\u00fcksek tutar. Re\u00e7ete yazan sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 bu ilac\u0131 hastalar\u0131na sunmak isterken sigorta \u015firketleri de (\u00f6zel \u015firketler veya ulusal sa\u011fl\u0131k programlar\u0131) bu ilac\u0131 kendi \u00fcyelerinin ve topluluklar\u0131n\u0131n kullan\u0131m\u0131na sunmak isterler. Ancak maliyet o kadar y\u00fcksektir ki bu ilac\u0131 sadece belirli say\u0131da ki\u015fiye re\u00e7ete edebilirler; b\u00fct\u00e7eleri daha fazlas\u0131n\u0131 kald\u0131ramayacakt\u0131r. Bu nedenle, bu ila\u00e7lardan faydalanabilecek ki\u015fi say\u0131s\u0131 s\u0131n\u0131rl\u0131 olur. K\u0131sacas\u0131; i\u015fin \u00f6z\u00fcnde \u00fcreticilerin, doktorlar\u0131n\/sigortac\u0131lar\u0131n ve hastalar\u0131n hedefleri birbiriyle \u00e7eli\u015fir.<\/p>\r\n<p>Yakla\u015f\u0131m\u0131m\u0131z, bu ila\u00e7lar\u0131 m\u00fcmk\u00fcn oldu\u011funca yayg\u0131n bir \u015fekilde eri\u015filebilir k\u0131lmak i\u00e7in <em>ortak bir hedef<\/em> do\u011frultusunda \u00e7al\u0131\u015fmak. Bunu yapmak i\u00e7in fiyatland\u0131rmam\u0131z\u0131 \u015feffaf, basit ve \u00e7ok daha d\u00fc\u015f\u00fck tutmay\u0131 ama\u00e7l\u0131yoruz. Biz daha fazla ila\u00e7 sat\u0131\u015f\u0131 yapabilece\u011fiz, re\u00e7ete yazan sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 ve sigorta \u015firketleri b\u00fct\u00e7elerini a\u015fmadan bu tedavileri daha fazla ki\u015fiye sunabilecek ve hastalar ise ya\u015famlar\u0131n\u0131 iyile\u015ftiren sa\u011fl\u0131k hizmetlerine eri\u015fme imkan\u0131 bulacak. B\u00f6ylece herkes fayda sa\u011flayabilecek.<\/p>\r\n<h2>\u00a0Bu yakla\u015f\u0131m, sa\u011fl\u0131k sistemleri ve hastalar i\u00e7in ne kadar b\u00fcy\u00fck bir fark yaratabilir?<\/h2>\r\n<p><strong>MN: <\/strong>Bunun muazzam bir fayda sa\u011flama potansiyeli var. Misyonumuz, hayat de\u011fi\u015ftiren ila\u00e7lar\u0131 \u00e7ok daha d\u00fc\u015f\u00fck fiyatlarla sunmak. \u201c\u00c7ok daha d\u00fc\u015f\u00fck fiyat\u201d derken d\u00f6rtte biri, \u00fc\u00e7te biri veya yar\u0131s\u0131 kadar daha d\u00fc\u015f\u00fck fiyatlardan bahsediyoruz. Bu \u00f6nemli bir fark demek. \u00d6rne\u011fin bir ila\u00e7 i\u00e7in 10 milyar ABD dolar\u0131 tutar\u0131nda bir k\u00fcresel harcama oldu\u011funu varsayal\u0131m; ki bu tutar pek \u00e7ok imm\u00fcn-enflamatuvar hastal\u0131k i\u00e7in gayet makul bir varsay\u0131m. \u0130lac\u0131m\u0131z, mevcut ilac\u0131n fiyat\u0131n\u0131n \u00fc\u00e7te biri olarak fiyatland\u0131r\u0131labilir; yani 10 milyar ABD dolar\u0131 de\u011ferinde bir pazarda, 6,6 milyar ABD dolar\u0131 \u00fczerinde potansiyel bir tasarruf s\u00f6z konusu olur. Elbette bir pazar\u0131n %100\u2019\u00fcne sahip olamay\u0131z; ancak ilac\u0131m\u0131z\u0131 \u00fc\u00e7te bir fiyatla piyasaya sunaca\u011f\u0131m\u0131z\u0131 d\u00fc\u015f\u00fcn\u00fcrsek pazar\u0131n sadece %15\u2019lik, yani 1,5 milyar dolarl\u0131k bir k\u0131sm\u0131na sahip olsak bile bu, bizim i\u00e7in 500 milyon dolar gelir ve sa\u011fl\u0131k sistemi i\u00e7in 1 milyar dolar tasarruf anlam\u0131na gelecektir. G\u00f6rd\u00fc\u011f\u00fcn\u00fcz gibi, bu \u015fekilde, m\u00fcthi\u015f bir potansiyeli olan bir i\u015f modeli in\u015fa edebilir ve daha \u00f6nce eri\u015femedikleri tedavilere eri\u015febilecek hastalar da dahil olmak \u00fczere ekosistemimizdeki t\u00fcm payda\u015flar i\u00e7in \u00f6nemli bir de\u011fer yaratabiliriz.<\/p>\r\n\r\n[caption id=\"attachment_95730\" align=\"aligncenter\" width=\"2267\"]<img class=\"size-full wp-image-95730\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/> Resimdekiler (Soldan sa\u011fa) EQRx Y\u00f6netim Kurulu \u0130cra Ba\u015fkan\u0131 Alexis Borisy ve EQRx \u0130cra Kurulu Ba\u015fkan\u0131 Melanie Nallicheri<br \/>\r\nFoto\u011fraf sahibi \u00a9 Fierce Biotech.[\/caption]\r\n\r\n<h2>EQRx, daha \u00f6nce ba\u015fkalar\u0131n\u0131n a\u015fmay\u0131 ba\u015faramad\u0131\u011f\u0131 bu engelleri nas\u0131l a\u015facak?<\/h2>\r\n<p><strong>MN: <\/strong>\u0130\u015f modelimizde, bunu yapmam\u0131za olanak sa\u011flayaca\u011f\u0131na inand\u0131\u011f\u0131m\u0131z \u00fc\u00e7 temel dayanak var. Birincisi, ilk g\u00fcnden itibaren tamamen farkl\u0131 bir maliyet yap\u0131s\u0131 olu\u015fturmaya odaklanmam\u0131z. Biz yeni bir i\u015fletmeyiz, bu sayede b\u00f6yle bir yap\u0131y\u0131 kurulu\u015f genelinde ba\u015ftan a\u015fa\u011f\u0131 uygulayabildik.<\/p>\r\n<p>\u0130kincisi, ila\u00e7lar\u0131n geli\u015ftirme maliyetlerini d\u00fc\u015f\u00fcrmek i\u00e7in, sekt\u00f6r\u00fcn halihaz\u0131rda sahip oldu\u011fu t\u00fcm ara\u00e7lar\u0131 kullanan operasyonel s\u00fcre\u00e7ler olu\u015fturuyor olmam\u0131z. \u00d6rne\u011fin, bir klinik \u00e7al\u0131\u015fma s\u0131ras\u0131nda hastalar\u0131 takip etmek i\u00e7in uzaktan izleme yakla\u015f\u0131mlar\u0131n\u0131 kullanabilirsiniz; bu da maliyetleri d\u00fc\u015f\u00fcren \u00e7ok daha h\u0131zl\u0131 ve verimli \u00e7al\u0131\u015fmalar yapabilmeniz anlam\u0131na gelir.<\/p>\r\n<p>Son olarak; bu benzersiz i\u015f modelinde, ilac\u0131n sat\u0131\u015f\u0131 i\u00e7in tipik bir sat\u0131\u015f ekibine ve y\u00fcksek promosyonlu bir yakla\u015f\u0131ma ihtiyac\u0131m\u0131z yok. Ortaklar\u0131m\u0131z, insanlar\u0131 ila\u00e7lar\u0131 sat\u0131n almaya ikna etmek i\u00e7in y\u00fczlerce sat\u0131\u015f eleman\u0131 g\u00f6ndermek yerine, ila\u00e7lar\u0131m\u0131z\u0131n sa\u011flad\u0131\u011f\u0131 tedaviyi ve eri\u015fimi art\u0131rmak i\u00e7in \u00e7al\u0131\u015facak. Bu pazar odakl\u0131 model, k\u00fcresel sa\u011fl\u0131k sekt\u00f6r\u00fcnde daha \u00f6nce g\u00f6r\u00fclmemi\u015f bir model.<\/p>\r\n<h2>Sn. Bouchenaki, sizi EQRx\u2019in Abdul Latif Jameel Health i\u00e7in iyi bir ortak olaca\u011f\u0131na ikna eden \u015fey neydi?<\/h2>\r\n<p><strong>AB:<\/strong> EQRx\u2019e yat\u0131r\u0131m yapma konusunu de\u011ferlendirirken EQRx\u2019in vizyonu, de\u011ferleri ve genel amac\u0131 ile b\u00fcy\u00fck bir uyum i\u00e7inde oldu\u011fumuzu fark ettik. Abdul Latif Jameel Health, geli\u015fmemi\u015f ve geli\u015fmekte olan \u00fclkelerde yenilik\u00e7i tedavilere eri\u015fimi h\u0131zland\u0131rmak i\u00e7in bir k\u00f6pr\u00fc olmay\u0131 ama\u00e7l\u0131yor. \u201cH\u0131zland\u0131rmak\u201d ve \u201ceri\u015fim sa\u011flamak\u201d bizim iki anahtar kelimemiz. Hayati \u00f6nem ta\u015f\u0131yan ila\u00e7lar\u0131 insanlara daha h\u0131zl\u0131 ula\u015ft\u0131rmak ve daha fazla insan\u0131n eri\u015fimine sunmak istiyoruz. Uygun fiyat konusu bunun \u00f6nemli bir par\u00e7as\u0131 ancak ila\u00e7lara ula\u015f\u0131m\u0131 engelleyen tek fakt\u00f6r bu de\u011fil.<\/p>\r\n<p>\u00c7al\u0131\u015fma hayat\u0131m boyunca, bula\u015f\u0131c\u0131 hastal\u0131klar\u0131 tedavi etmek i\u00e7in prevalans oranlar\u0131n\u0131n \u00e7ok y\u00fcksek oldu\u011fu \u00fclkelere tonlarca ila\u00e7 ba\u011f\u0131\u015flad\u0131\u011f\u0131m\u0131z ancak ne yaz\u0131k ki ihtiya\u00e7 duyan hastalar\u0131n bu ila\u00e7lara asla ula\u015famad\u0131\u011f\u0131 durumlara \u015fahit oldum. Yani uygun fiyat sorunu d\u0131\u015f\u0131nda ele al\u0131nmas\u0131 gereken daha fazla konu var.<\/p>\r\n<p>EQRx\u2019in yakla\u015f\u0131m\u0131nda ger\u00e7ekten ho\u015fumuza giden bir di\u011fer \u015fey ise gelecek i\u00e7in do\u011fru payda\u015flara odaklanarak, in\u015fa ettikleri yenilik\u00e7i i\u015f modelinde muhte\u015fem bir uyum sa\u011flad\u0131klar\u0131n\u0131 g\u00f6rm\u00fc\u015f olmam\u0131zd\u0131. Bu, fazlas\u0131yla destekledi\u011fimiz ve sorumlu oldu\u011fumuz b\u00f6lgelerde uygulamaya ge\u00e7irmeyi sab\u0131rs\u0131zl\u0131kla bekledi\u011fimiz bir vizyon ve strateji.<\/p>\r\n<h2>Sn. Nallicheri, ilk iki \u00fcr\u00fcn\u00fcn\u00fcz olan aumolertinib ve sugemalimab\u2019\u0131n her ikisi de kanser ilac\u0131. Neden bu ikisiyle ba\u015flamay\u0131 se\u00e7tiniz?<\/h2>\r\n<p><strong>MN: <\/strong>\u0130lk ba\u015flad\u0131\u011f\u0131m\u0131zda, ilk ilac\u0131m\u0131z\u0131 be\u015f y\u0131l i\u00e7inde hastalara sunmak istedi\u011fimizi s\u00f6yledik. Bu, portf\u00f6y\u00fcm\u00fcze dahil etmek istedi\u011fimiz ila\u00e7lar i\u00e7in pazar\u0131 ara\u015ft\u0131r\u0131rken d\u00fc\u015f\u00fcnd\u00fc\u011f\u00fcm\u00fcz bir durumdu. Aumolertinib ve sugemalimab ila\u00e7lar\u0131n\u0131n her ikisi de k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserinin yan\u0131 s\u0131ra di\u011fer kanser t\u00fcrleri i\u00e7in geli\u015ftirildi. Aumolertinib, EGFR kaynakl\u0131 mutasyonlar\u0131 olan hastalar i\u00e7in onkolojide uygulanan hedefli bir tedavi. Sugemalimab ise bir imm\u00fcn sistemi tedavisi. Bu, bug\u00fcn kanserde kullan\u0131ld\u0131\u011f\u0131n\u0131 bildi\u011fimiz en b\u00fcy\u00fck ila\u00e7 s\u0131n\u0131f\u0131.<\/p>\r\n<p>Her ikisi de muazzam bir etkinlik d\u00fczeyine ve g\u00fc\u00e7l\u00fc bir tolerasyon profiline sahip oldu\u011fu kan\u0131tlanm\u0131\u015f olan bu ila\u00e7lar konusunda \u00e7ok heyecanl\u0131y\u0131z.<\/p>\r\n<p>\u00dcstelik bu iki ila\u00e7 da ilk ba\u015fta belirledi\u011fimiz be\u015f y\u0131ll\u0131k hedefimizden \u00e7ok daha erken bir tarihte, 2023\u2019te kullan\u0131ma sunulabilir. Bu h\u0131zl\u0131 ilerleyi\u015f, bu ila\u00e7lar\u0131n ihtiya\u00e7 sahiplerine ula\u015ft\u0131r\u0131lmas\u0131 s\u00fcrecine ba\u015flamak i\u00e7in d\u00fcnyan\u0131n d\u00f6rt bir yan\u0131ndaki d\u00fczenleyici kurumlarla ve d\u00fcnya genelindeki ortaklar\u0131m\u0131zla g\u00f6r\u00fc\u015fmelere ba\u015flayabilece\u011fimiz anlam\u0131na geliyor. \u0130deal senaryo bu; yani ilk tahmin edilenden \u00e7ok daha erken bir tarihte, harika bir tolerasyon profiline ula\u015fan harika bir ila\u00e7. Bundan dolay\u0131, bu iki tedavi konusunda b\u00fcy\u00fck heyecan duyuyoruz.<\/p>\r\n<h2>Sn. Bouchenaki, bu ila\u00e7lar\u0131 ihtiya\u00e7 sahiplerine ula\u015ft\u0131rmak i\u00e7in Abdul Latif Jameel\u2019in k\u00fcresel faaliyet alan\u0131ndan nas\u0131l yararlanmay\u0131 planl\u0131yorsunuz?<\/h2>\r\n<p><strong>AB:<\/strong> Bu, tam da Abdul Latif Jameel Health\u2019in kurulu\u015f amac\u0131na uygun bir zorluk. \u0130novasyon zincirinin kritik bir par\u00e7as\u0131 haline gelmemiz, <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a>\u2019in vizyonuydu. \u00c7\u00fcnk\u00fc inovasyon sadece laboratuvarda olan bir \u015fey de\u011fil. Tabii ki ba\u015flang\u0131\u00e7 noktas\u0131 laboratuvar ancak inovasyon, bu tedavileri hastalara sunmak i\u00e7in yeni, daha h\u0131zl\u0131 ve etkili yollar bulmakla da ilgili. Bu inovasyon taahh\u00fcd\u00fcn\u00fc yerine getirdi\u011fimizi d\u00fc\u015f\u00fcn\u00fcyoruz. Bu ila\u00e7lar; hasta tedavisindeki d\u00f6n\u00fc\u015f\u00fcmde, ya\u015fam s\u00fcresinin uzat\u0131lmas\u0131nda, kanser tedavisinin daha iyi tolere edilmesinde kesinlikle merkezi bir role sahip olacak. Bu konuda taahh\u00fcd\u00fcm\u00fcz var ve bu taahh\u00fcd\u00fcm\u00fcz\u00fc yerine getirmeyi, bu inovasyon yolculu\u011funun ayr\u0131lmaz bir par\u00e7as\u0131 olarak g\u00f6r\u00fcyoruz.<\/p>\r\n<h2>\u00a0Hedeflerinize do\u011fru ilerlerken EQRx olarak kar\u015f\u0131la\u015faca\u011f\u0131n\u0131z\u0131 d\u00fc\u015f\u00fcnd\u00fc\u011f\u00fcn\u00fcz en b\u00fcy\u00fck zorluklar neler?<\/h2>\r\n<p><strong>MN<\/strong>: A\u015fmam\u0131z gereken ilk zorluk, ila\u00e7 katalo\u011fumuzu geli\u015ftirmek ve kurulu\u015fumuzu belirli bir \u00f6l\u00e7e\u011fe ula\u015ft\u0131rmak. Bunun i\u00e7in iki \u015fey yapmak gerekiyor. Birincisi, sekt\u00f6r\u00fcn genelindeki en iyi yeteneklerden baz\u0131lar\u0131n\u0131 \u015firketimize \u00e7ekmek. \u0130kincisi, istenen \u00f6l\u00e7e\u011fe h\u0131zla ula\u015fmak i\u00e7in \u00f6nemli miktarda sermayeyi harekete ge\u00e7irebilmek. En ba\u015f\u0131ndan beri bunun i\u00e7in ger\u00e7ekten \u00f6zenle \u00e7al\u0131\u015f\u0131yoruz. \u00c7al\u0131\u015fan taraf\u0131na bakacak olursak, hem ger\u00e7ekten heyecan verici olan sosyal misyonumuz hem de EQRx\u2019in giri\u015fimi ve yenilik\u00e7ili\u011fi \u00f6d\u00fcllendiren k\u00fclt\u00fcr\u00fc sayesinde ger\u00e7ekten benzersiz bir yetenek markas\u0131 olu\u015fturduk. Herkesin i\u015fleri farkl\u0131 \u015fekilde yapmaya \u00e7al\u0131\u015fmas\u0131n\u0131 te\u015fvik ediyoruz, elbette her bir fikrin ba\u015far\u0131yla sonu\u00e7lanmayabilece\u011finin fark\u0131nda olsak da yenilik\u00e7i yakla\u015f\u0131mlar\u0131 destekliyoruz.<\/p>\r\n<p><strong>AB: <\/strong>Bizim i\u00e7in temel zorluk, bu benzersiz \u015fekilde yenilik\u00e7i ve devrimsel nitelikteki modeli uygulamak. S\u0131n\u0131rlar\u0131n d\u0131\u015f\u0131na \u00e7\u0131kmal\u0131 ve insanlar\u0131n sahip oldu\u011fu ila\u00e7 piyasas\u0131 alg\u0131s\u0131n\u0131 de\u011fi\u015ftirmeliyiz. Hastane koridorlar\u0131nda dola\u015facak sat\u0131\u015f temsilcisi ordular\u0131 istemiyoruz. Bu, \u00fcretken bir \u015fekilde ge\u00e7irilebilecek zaman\u0131n b\u00fcy\u00fck k\u0131sm\u0131n\u0131 kaybetmek demek. Biz bunun yerine hizmete, e\u011fitime, da\u011f\u0131t\u0131ma odaklanmak istiyoruz. Hastalar\u0131n kendi sa\u011fl\u0131klar\u0131 konusunda s\u00f6z sahibi oldu\u011fu yeni bir ila\u00e7 sekt\u00f6r\u00fc modeli olu\u015ftururken sa\u011fl\u0131k otoriteleri, d\u00fczenleyiciler ve genel olarak sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131lar\u0131 ile ortakl\u0131k yapmak bizim i\u00e7in \u00f6nemli bir ba\u015far\u0131 etkeni olacak.<\/p>\r\n<p><img class=\"aligncenter size-full wp-image-95737\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\r\n<h2>\u00a0Son olarak\u2026 Her iki \u015firket i\u00e7in s\u0131radaki ad\u0131m nedir?<\/h2>\r\n<p><strong>MN:<\/strong> Katalo\u011fumuzu ve organizasyonumuzu olu\u015fturmaya odaklanaca\u011f\u0131z. \u015eu anda portf\u00f6y\u00fcm\u00fczde 10\u2019dan fazla ila\u00e7 program\u0131 var. Bunlardan be\u015fi aumolertinib ve sugemalimab\u2019\u0131n da dahil oldu\u011fu klinik a\u015famadaki programlar. Portf\u00f6y\u00fcm\u00fczde ba\u015fka bir imm\u00fcnoterapi se\u00e7ene\u011fi de bulunuyor. Bir meme kanseri ilac\u0131n\u0131n yan\u0131 s\u0131ra romatoid artrit ve atopik dermatit gibi maj\u00f6r imm\u00fcn-enflamatuvar hastal\u0131klar i\u00e7in bir ilac\u0131m\u0131z daha var. Bunlardan ba\u015fka, geli\u015ftirmekte oldu\u011fumuz erken a\u015famadaki birka\u00e7 ila\u00e7 program\u0131m\u0131z da var. Bunlar aras\u0131nda hem onkoloji hem de imm\u00fcn-enflamatuvar hastal\u0131klar yer al\u0131yor. Ayr\u0131ca, yak\u0131n zamanlarda baz\u0131 \u015firketlerle yapt\u0131\u011f\u0131m\u0131z \u00e7e\u015fitli ila\u00e7 m\u00fchendisli\u011fi i\u015f birliklerini duyurduk. 2025 veya 2026 y\u0131l\u0131na kadar, markal\u0131 ila\u00e7lar\u0131n trilyon dolarl\u0131k k\u00fcresel pazar\u0131ndaki harcamalar\u0131n %20\u2019sinden fazlas\u0131n\u0131 kar\u015f\u0131lamay\u0131 umuyoruz. Ve bu son derece heyecan verici bir beklenti.<\/p>\r\n<p><strong>AB:<\/strong> Bu yolculu\u011fun bir par\u00e7as\u0131 olmak i\u00e7in sab\u0131rs\u0131zlan\u0131yoruz. Melanie ve EQRx ekibi ile birlikte \u00e7al\u0131\u015fmay\u0131 ve stratejimizi uygulamaya koymay\u0131 sab\u0131rs\u0131zl\u0131kla bekliyoruz. As\u0131l i\u015fimizin ba\u015flad\u0131\u011f\u0131 yer buras\u0131 olacak. \u00c7ok heyecanl\u0131y\u0131z. Hastalar\u0131n bu heyecan verici yeni ila\u00e7lara m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede eri\u015febileceklerini g\u00f6rmeyi \u00e7ok isteriz. \u00d6n\u00fcm\u00fczdeki birka\u00e7 y\u0131l i\u00e7inde ve umar\u0131z daha sonraki d\u00f6nemlerde, bunu ba\u015farmak i\u00e7in elimizden geleni yapaca\u011f\u0131z.<\/p>"],"_content":[""],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_edit_last":["22"],"_wpml_media_duplicate":["1"],"_wpml_media_featured":["1"],"_yoast_wpseo_content_score":["60"],"_yoast_wpseo_estimated-reading-time-minutes":["11"]},"_links":{"self":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/wp-json\/wp\/v2\/perspectives\/15391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/wp-json\/wp\/v2\/media\/15377"}],"wp:attachment":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/tr\/wp-json\/wp\/v2\/media?parent=15391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}